In the claims:

1. (Presently amended) A compound of Formula I:

$$(CR^{1a}_{2})_{s} - Y$$
 $(CR^{1b}_{2})_{t} - Z$
 $(R^{5})_{w}$
 $(CR^{1b}_{2})_{t} - Z$
 $(R^{5})_{w}$
 $(CR^{1b}_{2})_{t} - Z$

wherein:

Rla and Rlb are independently selected from:

- 1) hydrogen,
- 2) unsubstituted or substituted C₁-C₁₀ alkyl,
- OR^3 ,
- 4) $N(R^3)_2$,
- 5) unsubstituted or substituted aryl,
- 6) unsubstituted or substituted heterocycle, and
- 7) unsubstituted or substituted C3-C10 cycloalkyl;

R1c is independently selected from:

- 1) hydrogen,
- 2) C₁-C₁₀ alkyl,
- 3) OR 3 ,
- 4) $N(R^3)_2$,
- 5) C3-C10 cycloalkyl,
- 6) aryl, and
- 7) heterocycle;

said alkyl, cycloalkyl, aryl and heterocycle is optionally substituted with at least one substituent selected from R⁷;

R² is independently selected from:

- 1) hydrogen,
- 2) unsubstituted or substituted C1-C10 alkyl,
- 3) $N(R^3)_2$, and
- 4) $OR_{\overline{3}}$
- 5) unsubstituted or substituted aryl, and
- 6) unsubstituted or substituted C3-C10 cycloalkyl;

R³ is independently selected from:

- 1) hydrogen, and
- 2) C_1 - C_{10} alkyl,
- 3) aryl,
- 4) heterocycle,
- 5) C3-C10-cycloalkyl,
- 6)——CF3;
- 7) C2-C6 alkenyl,
- 8) -- C2-C6-alkynyl,
- 9) $S(O)_{m}R^{6}$, and
- 10) C(O)R6;

said alkyl, eycloalkyl, aryl, heterocycle, alkynyl, and alkenyl is optionally substituted with at least one substituent selected from R⁷;

R⁵ is independently selected from:

- 1) hydrogen,
- 2) halogen,
- 3) $-(CR^{1}c_{2})_{n}OR^{3}$,
- 4) $-(CR^{1}c_{2})_{n}R^{6}$,
- 5) $-C(O)OR^3$,
- 6) $-C(O)R^3$,
- 7) $-C \equiv CR^3$,
- $_{8)}$ $_{-}R^{3}C = C(R^{3})_{2}$
- 9) $-OS(O)_mR^6$,
- 10) -NO₂,

- 11) $-(CR^{1}c_{2})_{n}N(R^{3})_{2}$,
- 12) $-N(R^3)C(O)R^3$,
- 13) $-N(R^3)S(O)_mR^6$,
- 14) $-(CR^{1}c_{2})_{n}NR^{3}(CR^{1}c_{2})_{n}C(O)NR^{3}2$,
- 15) $-O(CR^{1}c_{2})_{n}C(O)N(R^{3})_{2}$,
- 16) $-O(CR^{1}c_{2})_{n}C(O)OR^{3}$,
- 17) $-NR^3(CR^{1}c_2)_nN(R^3)_2$,
- 18) $-(CR^{1}c_{2})_{n}NR^{3}R^{6}OR^{3}$,
- 19) $-S(O)_{m}R^{6}$,
- 20) $-S(O)_mN(R^3)_2$,
- 21) -CN,
- 22) $-(CR^{1}c_{2})_{n}N(R^{3})(CR^{1}c_{2})_{n}R^{6}$, and
- 23) $-(CR^{1}c_{2})_{n}C(O)N(R^{3})_{2};$

R6 is independently selected from:

- 1) C₁-C₁₀ alkyl,
- 2) C3-C10 cycloalkyl,
- 3) aryl, and
- 4) heterocycle;

said, alkyl, cycloalkyl, aryl and heterocycle is optionally substituted with at least one substituent selected from R⁷;

R⁷ is independently selected from:

- 1) hydrogen,
- 2) unsubstituted or substituted C₁-C₁₀ alkyl,
- 3) unsubstituted or substituted C3-C10 cycloalkyl,
- 4) unsubstituted or substituted aryl,
- 5) halogen,
- OR^3 ,
- 7) CF₃,
- 8) unsubstituted or substituted heterocycle,
- 9) $S(O)_mN(R^3)_2$,
- 10) $C(O)OR^3$,
- 11) $C(O)R^3$,

- 12) CN,
- 13) $C(O)N(R^3)_2$,
- 14) $N(R^3)C(O)R^3$,
- 15) $S(O)_mR^6$, and
- 16) NO2;

Y and Z are independently selected from:

- 1) hydrogen,
- 2) R6,
- 3) OR^3 ,
- 4) $N(R^3)_{2}$
- 5) $C(O)OR^3$,
- 6) $C(O)N(R^3)_2$,
- 7) $C(O)R^3$,
- 8) halogen,
- 9) $N(R^3)(CR^{1}c_2)_nC(O)N(R^3)_2$,
- 10) $S(O)_mN(R^3)_2$,
- 11) $N(R^3)C(O)OR^3$,
- 12) $N(R^3)S(O)_mR^6$,
- 13) $N(R^3)C(O)R^3$,
- 14) $N(R^3)(CR^{1}c_2)_nR^3$,
- 15) $S(O)_{m}R^{6}$,
- 16) R⁶S(O)_mN(R³)₂,
- 17) $R^{6}S(O)_{m}R^{6}$,
- 18) $N(R^3) S(O)_m (CR^1c_2)_n R^6$,
- 19) $N(R^3)S(O)_mR^6OR^3$,
- 20) $N(R^3)C(O)N(R^3)_2$,
- 21) $N(R^3)C(O)R^6OR^3$,
- 22) $N(R^3)(CR^{1}c_2)_nR^6OR^3$,
- 23) $N(R^3)OR^3$, and
- 24) $N(R^3)S(O)_mR^6NO_2;$

m is independently 0, 1 or 2; n is independently 0 to 6; s is 0 to 6; t is 0 to 6; w is 0 to 4;

or a pharmaceutically acceptable salt or stereoisomer thereof.

2. (Presently amended) The compound according to Claim 1,

wherein:

R1a and R1b are independently selected from:

- 1) hydrogen,
- 2) unsubstituted or substituted C₁-C₁₀ alkyl,
- 3) unsubstituted or substituted aryl,
- 4) unsubstituted or substituted heterocycle, and
- 5) OR^3 ;

R1c is independently selected from:

- 1) hydrogen,
- 2) C₁-C₁₀ alkyl,
- 3) OR^3 ,
- 4) $N(R^3)_2$,
- 5) aryl, and
- 6) heterocycle;

said alkyl, aryl and heterocycle is optionally substituted with at least one substituent selected from R⁷;

R² is:

- 1)—H,
- 2) unsubstituted or substituted alkyl,
- 3) OR^3 , or
- 4) $N(R^3)_2$;

R³ is independently selected from:

1) hydrogen, and

- 2) C₁-C₁₀ alkyl₇
- 3) aryl,
- 4) heterocycle,
- 5) C3-C10 cycloalkyl,
- 6)——CF3;
- 7) $S(O)_m R^6$, and
- 8) C(O)R6;

said alkyl, cycloalkyl, aryl and heterocycle is optionally substituted with at least one substituent selected from R⁷;

R⁵ is independently selected from:

- 1) hydrogen,
- 2) halogen,
- 3) -OR³,
- 4) $-C(O)OR^{3}$,
- 5) $-C(O)R^3$,
- 6) $-C \equiv CR^3$,
- 7) $-R^3C = C(R^3)_2$,
- 8) $-OS(O)_mR^6$,
- 9) -NO₂,
- 10) $-N(R^3)_2$,
- 11) $-N(R^3)C(O)R^3$,
- 12) $-N(R^3)S(O)_mR^6$,
- 13) $-(CR^{1}c_{2})_{n}NR^{3}(CR^{1}c_{2})_{n}C(O)NR^{3}c_{2}$
- 14) $-O(CR^{1}c_{2})_{n}C(O)N(R^{3})_{2}$,
- 15) $-O(CR^{1}c_{2})_{n}C(O)OR^{3}$,
- 16) $-NR^3(CR^{1}c_2)_nN(R^3)_2$,
- 17) $-(CR^{1}c_{2})_{n}NR^{3}R^{6}OR^{3}$,
- 18) $-S(O)_{m}R^{6}$,
- 19) $-S(O)_{m}N(R^{3})_{2}$
- 20) -CN, and
- 21) $-(CR^{1}c_{2})_{n}N(R^{3})(CR^{1}c_{2})_{n}R^{6};$

or a pharmaceutically acceptable salt or stereoisomer thereof.

3. (Original) The compound according to Claim 2,

wherein:

R1a and R1b are independently selected from hydrogen, unsubstituted or substituted C1-C10 alkyl, OR3, and unsubstituted or substituted aryl;

R1c is independently selected from:

- 1) hydrogen,
- 2) C₁-C₁₀ alkyl,
- 3) OR^3 , and
- 4) aryl;

said alkyl and aryl is optionally substituted with at least one substituent selected from R7;

R² is:

- 1) OR^3 , or
- 2) $N(R^3)_2$;

R⁵ is independently selected from:

- 1) hydrogen,
- 2) $(CR^{1}c_{2})_{n}R^{6}$,
- 3) halogen,
- 4) $-(CR^{1}c_{2})_{n}OR^{3}$,
- 5) $-C(O)OR^3$,
- 6) $-C(O)R^3$,
- 7) $-C \equiv CR^3$,
- $_{8)}$ $_{-}R^{3}C = C(R^{3})_{2}$
- 9) $(CR^{1}c_{2})_{n}C(O)N(R^{3})_{2}$, and
- 10) $(CR^{1}c_{2})_{n}N(R^{3})_{2};$

Y is:

- 1) hydrogen,
- 2) R6,
- OR^3 ,
- 4) $C(O)R^3$,

- 5) $C(O)N(R^3)_2$, or
- 6) $N(R^3)_2$;

Z is:

- 1) hydrogen,
- 2) R6,
- 3) OR^3 ,
- 4) $N(R^3)_2$,
- 5) $C(O)OR^3$,
- 6) $C(O)N(R^3)_2$,
- 7) $C(O)R^3$,
- 8) halogen,
- 9) $N(R^3)(CR^1c_2)_nC(O)N(R^3)_2$,
- 10) $S(O)_mN(R^3)_2$,
- 11) $N(R^3)C(O)OR^3$,
- 12) $N(R^3)S(O)_mR^6$,
- 13) $N(R^3)C(O)R^3$,
- 14) $N(R^3)(CR^{1}c_2)_nR^3$, or
- 15) $S(O)_m R^6$;

n is independently 0 to 4;

or a pharmaceutically acceptable salt or stereoisomer thereof.

- 4. (Presently amended) A compound selected from:
- 5-Chloro-3-[(methylamino)sulfonyl]-1*H*-indole-2-carboxamide;
- 3-(Aminosulfonyl)-5-chloro-1*H*-indole-2-carboxamide;
- 5-Bromo-3-({methyl[(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3 yl)methyl] amino} sulfonyl)-1H-indole-2-carboxamide;
- $3-(\{[2-(Aminosulfonyl)ethyl]amino\} sulfonyl)-5-iodo-1 \\ \textit{H-} indole-2-carboxamide;$
- 3-[(Dimethylamino)sulfonyl]-5-methoxy-1H-indole-2-carboxamide;

- 5-Chloro-3-{[(2-phenethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;
- 5-Chloro-3-[(benzylamino)sulfonyl]-1*H*-indole-2-carboxamide;
- 5-Chloro-3-[(cyclohexylamino)sulfonyl]-1*H*-indole-2-carboxamide;
- 5-Chloro-3-[(1-naphthylamino)sulfonyl]-1*H*-indole-2-carboxamide;
- 5-Chloro-3-{[(3-phenylpropyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;
- 5-Chloro-3-[(ethylamino)sulfonyl]-1*H*-indole-2-carboxamide;
- 5-Chloro-3-[(propylamino)sulfonyl]-1*H*-indole-2-carboxamide;
- 5-Chloro-3-[(butylamino)sulfonyl]-1*H*-indole-2-carboxamide;
- 5-Chloro-3-[(pentylamino)sulfonyl]-1*H*-indole-2-carboxamide;
- 5-Chloro-3-{[ethyl(methyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;
- 5-Chloro-3-[(diethylamino)sulfonyl]-1*H*-indole-2-carboxamide;
- $\hbox{5-Chloro-3-[} (iso\hbox{-propylamino}) \hbox{sulfonyl]-1} H\hbox{-indole-2-carboxamide};$
- $\hbox{5-Chloro-3-[(cyclobutylamino)sulfonyl]-1} \textit{H-} indole-2-carboxamide;$
- 5-Chloro-3-[(cyclopentylamino)sulfonyl]-1*H*-indole-2-carboxamide;
- $5-Chloro-3-\{[(4-chlorophenyl)amino\} sulfonyl]-1 \\ \textit{H-} indole-2-carboxamide;$
- $5-Chloro-3-\{[(3-chlorophenyl)amino\} sulfonyl]-1 \\ H-indole-2-carboxamide;$
- 5-Chloro-3-{[(2-chlorophenyl)amino}sulfonyl]-1*H*-indole-2-carboxamide;
- $5-Chloro-3-\{[(4-chlorophenyl)methylamino\} sulfonyl]-1 \\ H-indole-2-carboxamide;$
- $5-Chloro-3-\{[(3-chlorophenyl)methylamino\} sulfonyl]-1 \\ \textit{H-} indole-2-carboxamide;$
- 5-Chloro-3-{[(2-chlorophenyl)methylamino}sulfonyl]-1*H*-indole-2-carboxamide;
- 5-Chloro-3-[(tert-butylamino)sulfonyl]-1H-indole-2-carboxamide;

- (\pm) -5-Chloro-3-[(pyrrolidin-3-ylamino)sulfonyl]-1*H*-indole-2-carboxamide;
- 5-Chloro-3-[(piperidin-4-ylamino)sulfonyl]-1*H*-indole-2-carboxamide;
- 5-Chloro-3-{[(1-methyl-1*H*-benzimidazol-2-yl)amino]sulfonyl}-1*H*-indole-2-carboxamide;
- 5-Chloro-3-[(benzamideamino)sulfonyl]-1*H*-indole-2-carboxamide;
- 5-Chloro-3-[(5-aminotetrazole)sulfonyl]-1*H*-indole-2-carboxamide;
- 5-Chloro-3-[(pyridin-4-ylamino)sulfonyl]-1*H*-indole-2-carboxamide;
- 5-Chloro-3-[(pyridin-2-ylamino)sulfonyl]-1*H*-indole-2-carboxamide;
- 5-Chloro-3-{[(2-methyoxyethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;
- 5-Chloro-3-[(dimethylamino)sulfonyl]-1*H*-indole-2-carboxamide;
- 3-({[2-(Aminosulfonyl)ethyl]amino}sulfonyl)-5-chloro-1*H*-indole-2-carboxamide;
- 5-Chloro-3-{[(2-hydroxyethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;
- 5-Chloro-3-{[(2-morpholin-4-ylethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;
- 5-Chloro-3-{[(2-methoxyethyl)(methyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;
- $5\text{-}Bromo-3-[(\{[2\text{-}(2\text{-}acetamide)amino}]\text{ethyl}\}\text{amino})\text{sulfonyl}]-1H\text{-}indole-2-carboxamide};$
- N-{[2-(Aminocarbonyl)-5-bromo-1H-indol-3-yl]sulfonyl}-N-methyl- β -alaninamide;
- 5-Bromo-3-[(methylamino)sulfonyl]-1*H*-indole-2-carboxamide;
- Ethyl N-{[2-(aminocarbonyl)-5-bromo-1H-indol-3-yl]sulfonyl} N-methyl- β -alaninate;
- 5-Bromo-3-{[cyclopropyl(methyl)amino]sulfonyl}-1H-indole-2-carboxamide;
- (\pm) -5-Bromo-3-{[methyl(tetrahydrofuran-3-yl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

5-Bromo-3-($\{\text{methyl}[2-(1H-1,2,4-\text{triazol-1-yl})\text{ethyl}]amino}\}$ sulfonyl)-1H-indole-2-carboxamide; 5-Bromo-3-{[methyl(tetrahydro-2*H*-pyran-4-yl)amino]sulfonyl}-1*H*-indole-2-carboxamide; (\pm) -5-Bromo-3- $\{[(1,4-\text{dioxan-2-ylmethyl})(\text{methyl})\text{amino}]$ sulfonyl $\}$ -1H-indole-2-carboxamide; 3-({[4-(Aminosulfonyl)benzyl]amino}sulfonyl)-5-bromo-1*H*-indole-2-carboxamide; 5-Chloro-3-{[iso-propyl(2-methoxyethyl)amino]sulfonyl}-1H-indole-2-carboxamide; 3-{[(2-Bromoethyl)(2-hydroxyethyl)amino]sulfonyl}-5-hydroxy-1*H*-indole-2-carboxamide; 3-{[(2-Bromoethyl)(2-hydroxyethyl)amino]sulfonyl}-5-methoxy-1*H*-indole-2-carboxamide; 5-Chloro-3-{[methoxy(methyl)amino]sulfonyl}-1*H*-indole-2-carboxamide; (\pm) -5-Chloro-3- $\{[(2,3-dihydroxypropyl)(methyl)amino]$ sulfonyl $\}$ -1H-indole-2-carboxamide; 5-Chloro-3-{[(2-hydroxyethyl)(methyl)amino]sulfonyl}-1*H*-indole-2-carboxamide; N-{[2-(Aminocarbonyl)-5-chloro-1*H*-indol-3-yl]sulfonyl}-N-methylglycine; N-{[2-(Aminocarbonyl)-5-chloro-1*H*-indol-3-yl]sulfonyl}-N-methylglycinamide; 5-Bromo-3-({[4-(methylsulfonyl)benzyl]amino}sulfonyl)-1*H*-indole-2-carboxamide; 3-[({2-[4-(Aminosulfonyl)phenyl]ethyl}amino)sulfonyl]-5-bromo-1*H*-indole-2-carboxamide; 3-{[(5-Amino-5-oxopentyl)amino]sulfonyl}-5-bromo-1*H*-indole-2-carboxamide; 3-({[2-(Aminosulfonyl)ethyl]amino}sulfonyl)-5-bromo-1*H*-indole-2-carboxamide; tert-Butyl 2-({[2-(aminocarbonyl)-5-bromo-1*H*-indol-3-yl]sulfonyl}amino)-ethylcarbamate; 3-{[(2-Aminoethyl)amino]sulfonyl}-5-bromo-1*H*-indole-2-carboxamide;

5-Bromo-3-{[methoxy(methyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

carboxamide;

5-Bromo-3-[({ethylsulfonylamino}ethylamino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Iodo-3-{[(2-{[(4-methoxyphenyl)sulfonyl]amino}ethyl)amino]sulfonyl}-1 H-indole-2-

- $5-Fluoro-3-\{[(2-\{[(4-methoxyphenyl)sulfonyl]amino\}ethyl)(methyl)amino]sulfonyl\}-1\\ H-indole-2-carboxamide;$
- 5-Bromo-3-{[(2-{[(4-nitrophenyl)sulfonyl]amino}ethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;
- 5-Bromo-3-({[2-({[(4-methoxyphenyl)amino]carbonyl}amino)ethyl]amino}sulfonyl)-1*H*-indole-2-carboxamide;
- 5-Bromo-3-[({3-[(4-chlorophenyl)thio]propyl}amino)sulfonyl]-1*H*-indole-2-carboxamide;
- 5-Bromo-3-[({3-[(4-chlorophenyl)thio]propyl}amino)sulfonyl]-1 *H*-indole-2-carboxamide;
- 5-Bromo-3-[({3-[(4-chlorophenyl)sulfonyl]propyl}amino)sulfonyl]-1 *H*-indole-2-carboxamide;
- 5-Bromo-3-[({propylsulfonylamino}ethylamino)sulfonyl]-1*H*-indole-2-carboxamide hydrochloride;
- 5-Bromo-3-{[(2-{[(4-methoxyphenyl)sulfonyl]amino}ethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;
- $5-Bromo-3-[(\{2-[(phenylsulfonyl)amino]ethyl\}amino)sulfonyl]-1 \\ H-indole-2-carboxamide;$
- $5\text{-}Bromo-3-[(\{2\text{-}[(methylsulfonyl]amino]ethyl\}amino)sulfonyl]-1}\\H-indole-2-carboxamide;$
- 3-[({2-[(Benzylsulfonyl)amino]ethyl}amino)sulfonyl]-5-bromo-1*H*-indole-2-carboxamide;
- 5-Bromo-3-{[(2-{[(3-methoxyphenyl)sulfonyl]amino}ethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;
- 5-Bromo-3-{[(2-{[(2,5-dimethoxyphenyl)sulfonyl]amino}ethyl)amino]sulfonyl}-1H-indole-2-carboxamide;

- 5-Bromo-3-{[(2-{[(5-bromo-2-methoxyphenyl)sulfonyl]amino}ethyl)amino] sulfonyl}-1*H*-indole-2-carboxamide;
- 5-Bromo-3-({[2-({[2-(trifluoromethoxy)phenyl]sulfonyl}amino)ethyl]amino} sulfonyl)-1 *H*-indole-2-carboxamide;
- 5-Bromo-3-{[(2-{[(2-methoxy-5-methylphenyl)sulfonyl]amino}ethyl)amino] sulfonyl}-1*H*-indole-2-carboxamide;
- 5-Bromo-3-{[(2-{[(4-cyanophenyl)sulfonyl]amino}ethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;
- 5-Bromo-3-{[(2-{[(4-chlorophenyl)sulfonyl]amino}ethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;
- $5-Bromo-3-\{[(2-\{[(3,4-dimethoxyphenyl)sulfonyl]amino\}ethyl)amino]sulfonyl\}-1\\H-indole-2-carboxamide;$
- 5-Bromo-3-[({3-[(phenylsulfonyl)amino]propyl}amino)sulfonyl]-1*H*-indole-2-carboxamide;
- $5-Bromo-3-\{[(3-\{[(4-methoxyphenyl)sulfonyl]amino\}propyl)amino]sulfonyl\}-1\\ H-indole-2-carboxamide;$
- $3-[(\{3-[(Benzylsulfonyl)amino]propyl\}amino)sulfonyl]-5-bromo-1 \\ H-indole-2-carboxamide;$
- 3-[({2-[(Aminocarbonyl)amino]ethyl}amino)sulfonyl]-5-bromo-1*H*-indole-2-carboxamide;
- $5-Bromo-3-\{[(2-\{[(4-bromophenyl)sulfonyl]amino\}ethyl)amino]sulfonyl\}-1\\H-indole-2-carboxamide;$
- 5-Bromo-3-[({2-[(thien-3-ylsulfonyl)amino]ethyl}amino)sulfonyl]-1*H*-indole-2-carboxamide;

- 5-Bromo-3-{[(2-{[(3-chlorobenzyl)sulfonyl]amino}ethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;
- 5-Bromo-3-{[(2-{[(2-phenylethyl)sulfonyl]amino}ethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;
- 5-Bromo-3-[({2-[(4-methoxybenzoyl)amino]ethyl}amino)sulfonyl]-1*H*-indole-2-carboxamide;
- 5-Bromo-3-[({2-[(4-methoxybenzyl)amino]ethyl}amino)sulfonyl]-1*H*-indole-2-carboxamide;
- 5-Bromo-3-[({2-[(4-methoxyphenyl)amino]ethyl}amino)sulfonyl]-1*H*-indole-2-carboxamide;
- 5-Bromo-3-[($\{2$ -[(4-methoxyphenyl)(methylsulfonyl)amino]ethyl $\}$ amino)sulfonyl]-1*H*-indole-2-carboxamide;
- 3-[({2-[Acetyl(4-methoxyphenyl)amino]ethyl}amino)sulfonyl]-5-bromo-1*H*-indole-2-carboxamide;
- 5-Iodo-3-{[cyclopropyl(methyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;
- 5-Iodo-3-[(cyclopropylamino)sulfonyl]-1*H*-indole-2-carboxamide;
- 5-Bromo-3-[(cyclopropylamino)sulfonyl]-1*H*-indole-2-carboxamide;
- 5-Iodo-3-{[methoxy(methyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;
- $(\pm)\text{-}5\text{-}Chloro-3-\{[(tetrahydro-2H\text{-}pyran-2\text{-}ylmethyl)amino}] \text{sulfonyl}\}\text{-}1H\text{-}indole-2\text{-}carboxamide};$
- (\pm) -5-Bromo-3- $\{[(tetrahydro-2H-pyran-2-ylmethyl)amino]sulfonyl\}-1H-indole-2-carboxamide;$
- $(\pm)\text{-}5\text{-}Iodo\text{-}3\text{-}\{[(tetrahydro\text{-}2H\text{-}pyran\text{-}2\text{-}ylmethyl)amino}] sulfonyl\}\text{-}1H\text{-}indole\text{-}2\text{-}carboxamide};$
- (\pm) -5-Chloro-3-{[methyl(tetrahydro-2*H*-pyran-2-ylmethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

- (\pm) -5-Bromo-3-{[methyl(tetrahydro-2*H*-pyran-2-ylmethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;
- (\pm)-5-Iodo-3-{[methyl(tetrahydro-2*H*-pyran-2-ylmethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;
- 5-Bromo-3-({[2-(tert-butylthio)ethyl]amino}sulfonyl)-1-*H*-indole-2-carboxamide;
- 5-chloro-3-{[methyl(tetrahydro-2H-pyran-4-yl)amino]sulfonyl}-1H-indole-2-carboxamide;
- 5-chloro-3-({[1-(2,3-dihydro-1,4-benzodioxin-2-yl)ethyl]amino}sulfonyl)-1H-indole-2-carboxamide;
- 5-chloro-3-[(tetrahydro-2H-pyran-4-ylamino)sulfonyl]-1H-indole-2-carboxamide;
- 5-chloro-3-{[(1,4-dioxan-2-ylmethyl)(methyl)amino]sulfonyl}-1H-indole-2-carboxamide;
- 5-chloro-3-({[(3-methyloxetan-3-yl)methyl]amino}sulfonyl)-1H-indole-2-carboxamide;
- 5-chloro-3-[(tetra hydrofuran-3-ylamino) sulfonyl]-1 H-indole-2-carboxamide;
- 5-chloro-3-({[(1,1-dioxidotetrahydrothien-3-yl)methyl]amino}sulfonyl)-1H-indole-2-carboxamide;
- 5-chloro-3-({[2-(3-phenyl-1*H*-1,2,4-triazol-5-yl)ethyl]amino}sulfonyl)-1*H*-indole-2-carboxamide;
- $5\text{-}chloro-3\text{-}(\{[2\text{-}(2\text{-}methoxyphenyl)ethyl]amino}\} sulfonyl)\text{-}1H\text{-}indole-2\text{-}carboxamide};$
- $5-chloro-3-(\{[3-(trifluoromethyl)benzyl]amino\} sulfonyl)-1 \\H-indole-2-carboxamide;$
- $5-chloro-3-(\{[2-(2,3-dihydro-1 H-indol-1-yl)ethyl]amino\} sulfonyl)-1 H-indole-2-carboxamide;$
- 5-chloro-3-({methyl[(1-methylpiperidin-3-yl)methyl]amino}sulfonyl)-1*H*-indole-2-carboxamide;

- 5-chloro-3-{[(2,3-dihydro-1,4-benzodioxin-2-ylmethyl) amino]sulfonyl}-1H-indole-2-carboxamide;
- 5-bromo-3-{[(3-ethoxypropyl) amino]sulfonyl}-1H-indole-2-carboxamide;
- 3-[({[2-(aminocarbonyl)-5-bromo-1H-indol-3-yl]sulfonyl}amino) methyl]-1-benzylpyrrolidine;
- $5\text{-}bromo3\text{-}(\{[(1\text{-}benzylpyrrolidin-3\text{-}yl)methyl]amino}\} sulfonyl)\text{-}1H\text{-}indole\text{-}2\text{-}carboxamide};$
- 5-bromo-3-{[(3-pyridin-3-ylpropyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;
- 1-[2-({[2-(aminocarbonyl)-5-bromo-1H-indol-3-yl]sulfonyl}amino)ethyl]-4-phenylpiperidine;
- 5-bromo-3-{[(3-cyclohexylpropyl)amino]sulfonyl}-1H-indole-2-carboxamide;
- 5-bromo-3-{[(4,4-diphenylbutyl)amino]sulfonyl}-1H-indole-2-carboxamide;
- 5-bromo-3-{[(3-butoxypropyl)amino]sulfonyl}-1H-indole-2-carboxamide;
- 5-bromo-3-{[(6,7,8,9-tetrahydro-5H-benzo[a][7]annulen-7-ylmethyl)amino]sulfonyl}-1H-indole-2-carboxamide;
- 5-bromo-3-({[3-(3,5-dimethyl-1H-pyrazol-1-yl)propyl]amino}sulfonyl)-1H-indole-2-carboxamide;
- 5-bromo-3-({[3-(4-tert-butoxyphenyl)propyl]amino} sulfonyl)-1H-indole-2-carboxamide;
- $5\text{-}bromo-3\text{-}(\{[4\text{-}(4\text{-}tert\text{-}butoxyphenyl)butyl}]amino\} sulfonyl)\text{-}1H\text{-}indole-2\text{-}carboxamide};$
- 5-bromo-3-{[(2-methoxy-1-methylethyl)amino]sulfonyl}-1H-indole-2-carboxamide;
- 5-bromo-3-{[(4-phenylbutyl)amino]sulfonyl}-1H-indole-2-carboxamide;
- 5-bromo-3-[({2-[(2,6-dichlorobenzyl)thio]ethyl}amino) sulfonyl]-1H-indole-2-carboxamide;
- $5\text{-}bromo-3\text{-}(\{[2\text{-}(tert\text{-}butylthio})ethyl]amino\} sulfonyl)\text{-}1H\text{-}indole\text{-}2\text{-}carboxamide};$
- 5-bromo-3-[({6-[(4-chlorobenzyl)amino]-6-oxohexyl}amino)sulfonyl]-1H-indole-2-carboxamide;

or a pharmaceutically acceptable salt or stereoisomer thereof.

- 5. (Original) The compound according to Claim 4, that is selected from:
- 5-Chloro-3-{[ethyl(methyl)amino]sulfonyl}-1*H*-indole-2-carboxamide

 $(\pm)\text{-}5\text{-}Bromo\text{-}3\text{-}\{[methyl(tetrahydrofuran\text{-}3\text{-}yl)amino}] sulfonyl\}\text{-}1H\text{-}indole\text{-}2\text{-}carboxamide}$

 $3-(\{[2-(Aminosulfonyl)ethyl]amino\} sulfonyl)-5-bromo-1 \\ \textit{H-} indole-2-carboxamide$

$$O = S$$
 $O = S$
 $O =$

 $5-Bromo-3-\{[(2-\{[(4-methoxyphenyl)sulfonyl]amino\}ethyl)amino]sulfonyl\}-1\\ H-indole-2-carboxamide$

 $5\text{-}bromo-3-\{[(3\text{-}butoxypropyl)amino]sulfonyl}\}-1H\text{-}indole-2-carboxamide}$

$$\begin{array}{c} CH_{3} \\ O \\ S = O \\ NH_{2} \\ N \\ O \\ H \end{array}$$

 $5\text{-}bromo-3\text{-}(\{[3\text{-}(4\text{-}tert\text{-}butoxyphenyl)propyl}]amino\} sulfonyl)-1H\text{-}indole-2\text{-}carboxamide}$

5-chloro-3-($\{[2-(3-phenyl-1H-1,2,4-triazol-5-yl)ethyl]amino\}$ sulfonyl)-1H-indole-2-carboxamide

or a pharmaceutically acceptable salt or stereoisomer thereof.

6. (Original) A pharmaceutical composition which is comprised of a compound in accordance with Claim 1 and a pharmaceutically acceptable carrier.

Serial No. 10/523,286 Case No. 21007YP Page 21

- 7. (Withdrawn by Examiner) A method of modulating the catalytic activity of protein kinases in a mammal in need thereof comprising contacting the protein kinase with a compound of Claim 1.
- 8. (Withdrawn by Examiner) The method of Claim 7 wherein the protein kinase is an RTK.
- 9. (Withdrawn by Examiner) The method of Claim 8, wherein the RTK is selected from IR, IGF-1R and IRR.
- 10. (Withdrawn by Examiner) A method of treating or preventing a PK-related disorder in a mammal in need thereof comprising administering to said mammal a therapeutically effective amount of a compound of Claim 1.
- 11. (Withdrawn by Examiner) A method of Claim 10, wherein the PK-related disorder is an IGF-1R-related disorder selected from:
 - 1) cancer,
 - 2) diabetes,
 - 3) an autoimmune disorder,
 - 4) a hyperproliferation disorder,
 - 5) aging,
 - 6) acromegaly, and
 - 7) Crohn's disease.
- 12. (Withdrawn by Examiner) A method of treating cancer in a mammal in need of such treatment comprising administering to said mammal a therapeutically effective amount of a compound of Claim 1.
- 13. (Withdrawn by Examiner) A method of treating retinal vascularization comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Claim 1.

Serial No. 10/523,286 Case No. 21007YP Page 22

- 14. (Withdrawn by Examiner) A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with a second compound selected from:
 - 1) an estrogen receptor modulator,
 - 2) an androgen receptor modulator,
 - 3) retinoid receptor modulator,
 - 4) a cytotoxic agent,
 - 5) an antiproliferative agent,
 - 6) a prenyl-protein transferase inhibitor,
 - 7) an HMG-CoA reductase inhibitor,
 - 8) an HIV protease inhibitor,
 - 9) a reverse transcriptase inhibitor, and
 - 10) an angiogenesis inhibitor.
- 15. (Withdrawn by Examiner) The method of Claim 14, wherein the second compound is an estrogen receptor modulator selected from tamoxifen and raloxifene.
- 16. (Withdrawn by Examiner) A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with radiation therapy.
- 17. (Withdrawn by Examiner) The method of Claim 16 wherein radiation therapy is also administered.
- 18. (Withdrawn by Examiner) A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 and paclitaxel or trastuzumab.
- 19. (Withdrawn by Examiner) A method of treating or preventing cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 and a GPIIb/IIIa antagonist.
 - 20. (Previously Canceled)

- 21. (Previously Canceled)
- 22. (Previously Canceled)
- 23. (Previously Canceled)